Genetic Disorders

AI-driven treatment approach and growing Fragile X Syndrome market size Healx Pharma has recently partnered with Boehringer Ingelheim to advance the treatment market and invest in R&D related to rare neurological disorders. Under the deal signed, Healx Artificial Intelligence (AI) drug discovery platform- Healnet will help in identifying the indications that can be treated with the use of therapies and drugs from the Boehringer Ingelheim’s pipeline. AI-powered biotechnology company, Healx has proven that its AI-driven Healnet has identified around eight drugs that can be repurposed to offer a potential and efficient cure for Rare neurological disorder...